U.S. antiviral drugmaker Gilead Sciences (GILD.O) will invest $5.1 billion in a major expansion of its partnership with Belgo-Dutch biotech Galapagos NV (GLPG.AS), news that lifted Galapagos’s shares 18 percent to an all-time high on Monday.
The move will bring Gilead’s new chief executive Daniel O’Day growth opportunities in Galapagos’s specialist areas including fibrosis and arthritis, and give Galapagos deep funds to develop and commercialize its drugs.
The two companies are going after inflammatory conditions, one of the most lucrative areas in the pharmaceuticals industry.
AbbVie’s Humira, used to treat rheumatoid arthritis and spondylitis, racked up nearly $20 billion in sales in 2018, while Amgen and Pfizer’s Enbrel still brings in $7 billion annually after 20 years on the market.
As part of the deal, Gilead will spend $1.1 billion to lift its Galapagos stake to 22% from 12.3%. The rest of the investment will be used to develop and commercialize its treatments for a 10-year period, the companies said.
“We chose to partner with Galapagos because of its pioneering target and drug discovery platform, proven scientific capabilities and outstanding team,” O’Day said in a statement.
Galapagos, which has more than 500 scientists, is part of a thriving biotech scene centered around Belgium, fueled by tax breaks and other incentives, with companies spun out of universities now listed on the local stock exchange.
The deal follows a spate of biotech mergers last year including the acquisition of fellow Belgian biotech Ablynx by French drugmaker Sanofi for 3.9 billion euros ($4.4 billion) after a bidding war with Novo Nordisk.
Galapagos’s most advanced drug in development is filgotinib, an experimental compound being advanced for rheumatoid arthritis and inflammatory bowel disease that Gilead intends to submit to the U.S. Food and Drug Administration this year.
The two companies first partnered four years ago to develop a drug targeting inflammatory diseases, with Gilead paying more than $2 billion for the development of filgotinib, as well as an equity stake in the European firm.
Gilead is paying a 10 percent premium to Friday’s closing price for the increased stake in Galapagos, but has a 10-year standstill agreement preventing it from raising its stake above 29.9 percent.
“We see a logical rationale for the deal and believe that over time the closer relationship should help both companies,” RBC analyst Brian Abrahams wrote in a note, reiterating his “buy” recommendation on Gilead stock.
Shares in Galapagos traded 16.8 percent higher at 149.70 euros at 0955 GMT.
Galapagos said it would also seek shareholder approval to allow Gilead to further increase its ownership to up to 29.9%.
The companies will share future development costs for filgotinib equally, replacing the 80-20 cost split provided by the original agreement, they said, with Galapagos gaining a broader role in the treatment’s commercialization in Europe.
Gilead will get access to Galapagos’s drug pipeline outside of Europe.
Gilead will nominate two people to Galapagos’ board.
Barclays, Centerview Partners and Lazard acted as financial advisers to Gilead while Moelis & Co and Morgan Stanley advised Galapagos.
By Ismail Shakil
Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.
Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.